114 related articles for article (PubMed ID: 38653365)
1. No effect of liraglutide on high density lipoprotein apolipoprotein AI kinetics in patients with type 2 diabetes.
Duvillard L; Pais de Barros JP; Rouland A; Simoneau I; Denimal D; Bouillet B; Petit JM; Vergès B
Diabetes Metab; 2024 May; 50(3):101535. PubMed ID: 38653365
[TBL] [Abstract][Full Text] [Related]
2. In vivo evidence for the role of lipoprotein lipase activity in the regulation of apolipoprotein AI metabolism: a kinetic study in control subjects and patients with type II diabetes mellitus.
Frénais R; Nazih H; Ouguerram K; Maugeais C; Zaïr Y; Bard JM; Charbonnel B; Magot T; Krempf M
J Clin Endocrinol Metab; 2001 May; 86(5):1962-7. PubMed ID: 11344192
[TBL] [Abstract][Full Text] [Related]
3. Influence of atorvastatin on apolipoprotein E and AI kinetics in patients with type 2 diabetes.
Bach-Ngohou K; Ouguerram K; Frénais R; Maugère P; Ripolles-Piquer B; Zaïr Y; Krempf M; Bard JM
J Pharmacol Exp Ther; 2005 Oct; 315(1):363-9. PubMed ID: 16014756
[TBL] [Abstract][Full Text] [Related]
4. Chronic hyperinsulinemia does not increase the production rate of high-density lipoprotein apolipoprotein AI: evidence from a kinetic study in patients with insulinoma.
Duvillard L; Florentin E; Pont F; Petit JM; Baillot-Rudoni S; Penfornis A; Vergès B
Arterioscler Thromb Vasc Biol; 2013 Oct; 33(10):2460-5. PubMed ID: 23908245
[TBL] [Abstract][Full Text] [Related]
5. High density lipoprotein apolipoprotein AI kinetics in NIDDM: a stable isotope study.
Frénais R; Ouguerram K; Maugeais C; Mahot P; Maugère P; Krempf M; Magot T
Diabetologia; 1997 May; 40(5):578-83. PubMed ID: 9165227
[TBL] [Abstract][Full Text] [Related]
6. Differential regulation of lipoprotein kinetics by atorvastatin and fenofibrate in subjects with the metabolic syndrome.
Watts GF; Barrett PH; Ji J; Serone AP; Chan DC; Croft KD; Loehrer F; Johnson AG
Diabetes; 2003 Mar; 52(3):803-11. PubMed ID: 12606523
[TBL] [Abstract][Full Text] [Related]
7. Increased apolipoprotein AI production rate and redistribution of high-density lipoprotein size induced by estrogen plus progestin as oral contraceptive.
Duvillard L; Dautin G; Florentin E; Jeannin A; Pais de Barros JP; Lagrost L; Petit JM; Gambert P; Vergès B
J Clin Endocrinol Metab; 2009 Dec; 94(12):4891-7. PubMed ID: 19858317
[TBL] [Abstract][Full Text] [Related]
8. Liraglutide Increases the Catabolism of Apolipoprotein B100-Containing Lipoproteins in Patients With Type 2 Diabetes and Reduces Proprotein Convertase Subtilisin/Kexin Type 9 Expression.
Vergès B; Duvillard L; Pais de Barros JP; Bouillet B; Baillot-Rudoni S; Rouland A; Petit JM; Degrace P; Demizieux L
Diabetes Care; 2021 Apr; 44(4):1027-1037. PubMed ID: 33531418
[TBL] [Abstract][Full Text] [Related]
9. Apolipoprotein E kinetics: influence of insulin resistance and type 2 diabetes.
Bach-Ngohou K; Ouguerram K; Nazih H; Maugère P; Ripolles-Piquer B; Zaïr Y; Frénais R; Krempf M; Bard JM
Int J Obes Relat Metab Disord; 2002 Nov; 26(11):1451-8. PubMed ID: 12439646
[TBL] [Abstract][Full Text] [Related]
10. Inefficiency of insulin therapy to correct apolipoprotein A-I metabolic abnormalities in non-insulin-dependent diabetes mellitus.
Duvillard L; Pont F; Florentin E; Gambert P; Vergès B
Atherosclerosis; 2000 Sep; 152(1):229-37. PubMed ID: 10996359
[TBL] [Abstract][Full Text] [Related]
11. High-density lipoprotein subspecies between patients with type 1 diabetes and type 2 diabetes without / with intensive insulin therapy.
Fukui T; Hirano T
Endocr J; 2012; 59(7):561-9. PubMed ID: 22504174
[TBL] [Abstract][Full Text] [Related]
12. Effect of niacin on high-density lipoprotein apolipoprotein A-I kinetics in statin-treated patients with type 2 diabetes mellitus.
Pang J; Chan DC; Hamilton SJ; Tenneti VS; Watts GF; Barrett PH
Arterioscler Thromb Vasc Biol; 2014 Feb; 34(2):427-32. PubMed ID: 24285582
[TBL] [Abstract][Full Text] [Related]
13. Rosuvastatin 20 mg restores normal HDL-apoA-I kinetics in type 2 diabetes.
Vergès B; Florentin E; Baillot-Rudoni S; Petit JM; Brindisi MC; Pais de Barros JP; Lagrost L; Gambert P; Duvillard L
J Lipid Res; 2009 Jun; 50(6):1209-15. PubMed ID: 19168444
[TBL] [Abstract][Full Text] [Related]
14. Adiponectin is an important determinant of apoA-I catabolism.
Vergès B; Petit JM; Duvillard L; Dautin G; Florentin E; Galland F; Gambert P
Arterioscler Thromb Vasc Biol; 2006 Jun; 26(6):1364-9. PubMed ID: 16574896
[TBL] [Abstract][Full Text] [Related]
15. Effect of liraglutide administration and a calorie-restricted diet on lipoprotein profile in overweight/obese persons with prediabetes.
Ariel D; Kim SH; Abbasi F; Lamendola CA; Liu A; Reaven GM
Nutr Metab Cardiovasc Dis; 2014 Dec; 24(12):1317-22. PubMed ID: 25280957
[TBL] [Abstract][Full Text] [Related]
16. Elevated Levels of Apolipoprotein CIII Increase the Risk of Postprandial Hypertriglyceridemia.
Guan Y; Hou X; Tian P; Ren L; Tang Y; Song A; Zhao J; Gao L; Song G
Front Endocrinol (Lausanne); 2021; 12():646185. PubMed ID: 33967959
[TBL] [Abstract][Full Text] [Related]
17. High-density lipoprotein apolipoprotein A-I kinetics in obese insulin resistant patients. An in vivo stable isotope study.
Pont F; Duvillard L; Florentin E; Gambert P; Vergès B
Int J Obes Relat Metab Disord; 2002 Sep; 26(9):1151-8. PubMed ID: 12187390
[TBL] [Abstract][Full Text] [Related]
18. Efficacy and safety of liraglutide for overweight adult patients with type 1 diabetes and insufficient glycaemic control (Lira-1): a randomised, double-blind, placebo-controlled trial.
Dejgaard TF; Frandsen CS; Hansen TS; Almdal T; Urhammer S; Pedersen-Bjergaard U; Jensen T; Jensen AK; Holst JJ; Tarnow L; Knop FK; Madsbad S; Andersen HU
Lancet Diabetes Endocrinol; 2016 Mar; 4(3):221-232. PubMed ID: 26656289
[TBL] [Abstract][Full Text] [Related]
19. Relationships between serum lipid, lipoprotein, triglyceride-rich lipoprotein, and high-density lipoprotein particle concentrations in post-renal transplant patients.
Kimak E; Hałabiś M; Baranowicz-Gaszczyk I
J Zhejiang Univ Sci B; 2010 Apr; 11(4):249-57. PubMed ID: 20349521
[TBL] [Abstract][Full Text] [Related]
20. In vivo evidence for increased apolipoprotein A-I catabolism in subjects with impaired glucose tolerance.
Pietzsch J; Julius U; Nitzsche S; Hanefeld M
Diabetes; 1998 Dec; 47(12):1928-34. PubMed ID: 9836526
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
